Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II

Journal of Virology

Volumn 82, Issue 13, 2008, Pages 6631-6643

  Lai, Chih Yun ^a   Tsai, Wen Yang ^a   Lin, Su Ru ^a   Kao, Chuan Liang ^a   Hu, Hsien Ping ^a   King, Chwan Chuen ^b   Wu, Han Chung ^c   Chang, Gwong Jen ^d   Wang, Wei Kung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN E ANTIBODY; NONSTRUCTURAL PROTEIN 1; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE VIRUS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SEROTYPING; TAIWAN; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANTIBODIES, VIRAL; BLOTTING, WESTERN; CELL LINE; CROSS REACTIONS; DENGUE VIRUS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; MUTATION, MISSENSE; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; TAIWAN; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; MIRIDAE;

EID: 45749131789     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00316-08     Document Type: Article

References (60)

1. Alvarez, M., R. Rodriguez-Roche, L. Bernardo, S. Vazquez, L. Morier, D. Gonzalez, O. Castro, G. Kouri, S. B. Halstead, and M. G. Guzman. 2006. Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 75:1113-1117.
2. Beasley, D. W. C., and A. D. T. Barrett. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76:13097-13100.
3. Bray, M., and C. J. Lai. 1991. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185:505-508.
4. Burke, D. S., A. Nisalak, D. E. Johnson, and R. M. Scott. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:172-180.
5. Churdboonchart, V., N. Bhamarapravati, S. Peampramprecha, and S. Sirinavin. 1991. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 44:481-493.
6. Crill, W. D., and G. J. J. Chang. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78:13975-13986.
7. Crill, W. D., and J. T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
8. Endy, T. P., A. Nisalak, S. Chunsuttitwat, D. W. Vaughn, S. Green, F. A. Ennis, A. L. Rothman, and D. H. Library. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000.
9. Falconar, A. K. 1997. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesion proteins and binds to human endothelial cells: potential implications in hemorrhagic fever pathogenesis. Arch. Virol. 143:897-916.
10. Falconar, A. K., and P. R. Young. 1991. Production of dimer-specific and dengue virus group cross-reactive mouse monoclonal antibodies to the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 72:961-965.
11. Falgout, B., M. Bray, J. J. Schlesinger, and C. J. Lai. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 64:4356-4363.
12. Goncalvez, A. P., R. H. Purcell, and C. J. Lai. 2004. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J. Virol. 78:12919-12928.
13. Gonzalez, D., O. E. Castro, G. Kouri, J. Perez, E. Martinez, S. Vazquez, D. Rosario, R. Cancio, and M. G. Guzman. 2005. Classical dengue hemorrhagic fever resulting from two dengue infection spaced 20 years or more apart: Havana, dengue 3 epidemic, 2001-2002. Int. J. Infect. Dis. 9:280-285.
14. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
15. Gubler, D. J. 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:100-103.
16. Guzman, M. G., M. Alvarez, R. Rodriguez-Roche, L. Bernardo, T. Montes, S. Vazquez, L. Morier, A. Alvarez, E. A. Gould, G. Kouri, and S. B. Halstead. 2007. Neutralizing antibodies after infection with dengue 1 virus. Emerg. Infect. Dis. 13:282-286.
17. Guzman, M. G., and G. Kouri. 2002. Dengue: an update. Lancet Infect. Dis. 2:33-42.
18. Guzman, M. G., G. P. Kouri, J. Bravo, M. Soler, S. Vazquez, and L. Morier. 1990. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42:179-184.
19. Guzman, M. G., G. Kouri, L. Valdes, J. Bravo, M. Alvarez, S. Vazquez, I. Delgado, and S. B. Halstead. 2000. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152:793-799.
20. Guzman, M. G., G. Kouri, L. Valdes, J. Bravo, S. Vazquez, and S. B. Halstead. 2002. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11:223-227.
21. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
22. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
23. Halstead, S. B., and E. J. O'Rourke. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741.
24. Henchal, E. A., M. K. Gentry, J. M. McCown, and W. E. Brandt. 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am. J. Trop. Med. Hyg. 31:830-836.
25. Henchal, E. A., L. S. Henchal, and J. J. Schlesinger. 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69:2101-2107.
26. Hu, H. P., S. C. Hsieh, C. C. King, and W. K. Wang. 2007. Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses. Virology 368:376-387.
27. Huang, K. J., Y. C. Yang, Y. S. Lin, J. H. Huang, H. S. Liu, T. M. Yeh, S. H. Chen, C. C. Liu, and H. Y. Lei. 2006. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 176:2825-2832.
28. Innis, B. L., V. Thirawuth, and C. Hemachudha. 1989. Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus. Am. J. Trop. Med. Hyg. 40:676-687.
29. Kochel, T. J., D. M. Watts, S. B. Halstead, C. G. Hayes, A. Espinoza, V. Felices, R. Caceda, C. T. Bautista, Y. Montoya, S. Douglas, and K. L. Russell. 2002. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360:310-312.
30. Kuno, G., A. V. Vorndam, D. J. Gubler, and I. Gomez. 1990. Study of anti-dengue NS1 antibody by Western blot. J. Med. Virol. 32:102-108.
31. Lai, C. Y., H. P. Hu, C. C. King, and W. K. Wang. 2008. Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J. Biomed. Sci. 15:15-27.
32. Lin, C. F., S. C. Chiu, Y. L. Hsiao, S. W. Wen, H. Y. Lei, A. L. Shiau, H. S. Liu, T. M. Yeh, S. H. Chen, C. C. Liu, and Y. S. Lee. 2005. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J. Immunol. 174:395-403.
33. Lin, C. F., H. Y. Lei, A. L. Shiau, H. S. Liu, T. M. Yeh, S. H. Chen, C. C. Liu, S. C. Chiu, and Y. S. Lee. 2002. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J. Immunol. 169:657-664.
34. Lindenbach, B. D., and C. M. Rice. 2001. Flaviviridae: the viruses and their replication, p. 991-1041. In D. M. Knipe, P. M. Howley, and D. E. Griffin (ed.), Fields virology. Lippincott William & Wilkins, Philadelphia, PA.
35. Mandl, C. W., F. Guirakhoo, H. Holzmann, F. X. Heinz, and C. Kunz. 1989. Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J. Virol. 63:564-571.
36. Mazumder, R., Z. Z. Hu, C. R. Vinayaka, J. L. Sagripanti, S. D. W. Frost, S. L. K. Pond, and C. H. Wu. 2007. Computational analysis and identification of amino acid sites in dengue E protein relevant to development of diagnostics and vaccines. Virus Genes 35:175-186.
37. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. Aligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100:6986-6991.
38. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
39. Morens, D. M. 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:500-512.
40. Morens, D. M., C. N. Venkateshan, and S. B. Halstead. 1987. Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J. Gen. Virol. 68:91-98.
41. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
42. Oliphant, T., G. E. Nybakken, M. Engle, O. Xu, C. A. Nelson, S. Sukupolvi-Petty, A. Marri, B. E. Lachmi, U. Olshevsky, D. H. Fremont, T. C. Pierson, and M. Diamond. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80:12149-12159.
43. Qu, X., W. Chen, T. Maguire, and F. Austin. 1993. Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in baculovirus expression system. J. Gen. Virol. 74:89-97.
44. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
45. Roehrig, J. T., R. A. Bolin, and R. G. Kelly. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328.
46. Roehrig, J. T., A. J. Johnson, A R. Hunt, R. A. Bolin, and M. C. Chu. 1990. Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology 177:668-675.
47. Roehrig, J. T., K. E. Volpe, J. Squires, A. R. Hunt, B. S. Davis, and G. J. J. Chang. 2004. Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J. Virol. 78:2648-2652.
48. Sabin, A. B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
49. Sanchez, M. D., T. C. Pierson, D. McAllister, S. L. Hanna, B. A. Puffer, L. E. Valentine, M. M. Murtadha, J. A. Hoxie, and R. W. Doms. 2005. Characterization of neutralizing antibodies to West Nile virus. Virology 336:70-82.
50. Sangkawibha, N., S. Rojanasuphot, S. Ahandrik, S. Viriyapongse, S. Jata nasen, V. Salitul, B. Phanthumachinda, and S. B. Halstead. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120:653-669.
51. Schlesinger, J. J., M. W. Brandriss, and E. E. Walsh. 1987. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68:853-857.
52. Se-Thoe, S. Y., M. M. Ng, and A. E. Ling. 1999. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J. Med. Virol. 57:322-330.
53. Shu, P. Y., L. K. Chen, S. F. Chang, Y. Y. Yueh, L. Chow, L. J. Chien, C. Chin, T. H. Lin, and J. H. Huang. 2003. Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin. Diagn. Lab. Immunol. 10:622-630.
54. Stiasny, K., S. Kiermayr, H. Holzmann, and F. X. Heinz. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557-9568.
55. Sukupolvi-Petty, S., K. Austin, W. E. Purtha, T. Oliphant, G. E. Nybakken, J. J. Schlesinger, J. T. Roehrig, G. D. Gromowski, A. D. Barrett, D. H. Fremont, and M. Diamond. 2007. Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
56. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
57. Throsby, M., C. Geuijen, J. Goudsmit, A. Q. Bakker, J. Korimbocus, R. A. Kramer, M. C. der Horst, M. de Jong, M. Jongeneelen, S. Thijsse, R. Smit, T. J. Visser, N. Bijl, W. E. Marissen, M. Loeb, D. J. Kelvin, W. Preiser, J. ter Meulen, and J. der Kruif. 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J. Virol. 80:6982-6992.
58. Valdes, K., M. Alvarez, M. Pupo, S. Vazquez, R. Rodriguez, and M. G. Guzman. 2000. Human dengue antibodies against structural and nonstructural proteins. Clin. Diagn. Lab. Immunol. 7:856-857.
59. Wang, W. K., H. L. Chen, C. F. Yang, S. C. Hsieh, C. C. Juan, S. M. Chang, C. C. Yu, L. H. Lin, J. H. Huang, and C. C. King. 2006. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin. Infect. Dis. 43:1023-1030.
60. World Health Organization. 1997. Dengue hemorrhagic fever, diagnosis, treatment and control, 2nd ed. World Health Organization, Geneva, Switzerland.